WEST PALM BEACH, FL, May 15, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a digital health company advancing personalized medicine through innovative population health screening and point of care diagnostic tools in primary care, today announced its financial results for the three months ended March 31, 2025.
Financial Highlights for Q1 2025:
The strong year-over-year growth was driven by a diversified revenue base including:
| Revenue Breakdown | Q1 2025 | Q1 2024 | % Change | |||||||||
| Allergy Diagnostics | $ | 264,913 | $ | 237,066 | +11.7 | % | ||||||
| ISP Services | $ | 162,502 | $ | 127,004 | +28.0 | % | ||||||
| Immunotherapy | $ | 97,329 | $ | 86,325 | +12.8 | % | ||||||
| Clinical Study | $ | 89,100 | – | New | ||||||||
| Subscriptions | $ | 9,285 | $ | 18,370 | -49.5 | % | ||||||
| Shipping & Handling | $ | 9,970 | $ | 9,959 | – | |||||||
| Training & Other | $ | 12,320 | $ | 9,863 | +24.9 | % | ||||||
| Total | $ | 645,419 | $ | 488,587 | +32.1 | % | ||||||
“We’re pleased to report strong top-line growth and a significant improvement in gross profitability for the first quarter,” said Troy Grogan, CEO of QHSLab. “Our multi-pronged revenue model is beginning to show the structural advantages we anticipated. As our integrated clinical services and diagnostics continue gaining traction in primary care, we’re focused on driving sustainable margin expansion and unlocking shareholder value.”
The increase in gross margin reflects a favorable product mix, operational synergies across the company’s core offerings, and increased revenue from high-margin services such as ISP and clinical research contracts. QHSLab expects continued variability in gross margin depending on timing and mix of new product introductions, customer profile, and negotiated pricing, but remains focused on achieving long-term profitability and scale.
For more information about QHSLab and our healthcare solutions, please visit www.qhslab.com.
About QHSLab, Inc.
QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also increasing their revenues.
Forward-Looking Statements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations Contact:
Brett Maas, Managing Principal, Hayden IR, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
646-536-7331
https://twitter.com/QHSLabInc
| Last Trade: | US$0.20 |
| Daily Change: | 0.02 11.23 |
| Daily Volume: | 2,000 |
| Market Cap: | US$2.120M |
December 13, 2024 November 14, 2024 September 17, 2024 August 14, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
